Literature DB >> 24570955

Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats.

André F Nascimento1, Blanche C Ip2, Renata A M Luvizotto1, Helmut K Seitz3, Xiang-Dong Wang2.   

Abstract

Chronic alcohol intake decreases adiponectin and sirtuin 1 (SIRT1) expressions, both of which have been implicated in various biological processes including inflammation, apoptosis and metabolism. We have previously shown that moderate consumption of alcohol aggravates liver inflammation and apoptosis in rats with pre-existing nonalcoholic steatohepatitis (NASH). This study investigated whether moderate alcohol intake alters SIRT1 activity, adiponectin/Adiponectin receptor (AdipoR)-related signaling and lipid metabolism in a pre-existing NASH status. Sprague-Dawley rats were fed with a high-fat diet (71% energy from fat) for 6 weeks to induce NASH then subsequently divided into 2 sub-groups: fed either a modified high-fat diet (HFD, 55% energy from fat) or a modified high-fat alcoholic diet (HFA, 55% energy from fat and 16% energy from ethanol) for an additional 4 weeks. We observed in comparison to HFD group, HFA increased hepatic nuclear SIRT1 protein but decreased its deacetylase activity. SREBP-1c protein expression and FAS mRNA levels were significantly upregulated, while DGAT1/2 and CPT-I mRNA levels were downregulated in the livers of HFA compared to HFD. Although hepatic AdipoR1 decreased, HFA did not alter AdipoR2 and their downstream signaling. There were no significant changes in plasma adiponectin and free fatty acids (FFA), as well as adiponectin expression in adipose tissue between the two groups. The present study indicates that suppression in SIRT1 deacetylase activity contributes to alcohol-exacerbated hepatic inflammation and apoptosis in rats with pre-existing NASH. In addition, moderate alcohol intake did not modulate adiponectin/AdipoR signaling axis in this model.

Entities:  

Keywords:  Adiponectin; alcohol consumption; nonalcoholic steatohepatitis (NASH); rats; sirtuin-1 (SIRT1)

Year:  2013        PMID: 24570955      PMCID: PMC3924692          DOI: 10.3978/j.issn.2304-3881.2013.07.05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  26 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  Sirtuin 1 in lipid metabolism and obesity.

Authors:  Thaddeus T Schug; Xiaoling Li
Journal:  Ann Med       Date:  2011-02-24       Impact factor: 4.709

3.  Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1.

Authors:  Masato Iwabu; Toshimasa Yamauchi; Miki Okada-Iwabu; Koji Sato; Tatsuro Nakagawa; Masaaki Funata; Mamiko Yamaguchi; Shigeyuki Namiki; Ryo Nakayama; Mitsuhisa Tabata; Hitomi Ogata; Naoto Kubota; Iseki Takamoto; Yukiko K Hayashi; Naoko Yamauchi; Hironori Waki; Masashi Fukayama; Ichizo Nishino; Kumpei Tokuyama; Kohjiro Ueki; Yuichi Oike; Satoshi Ishii; Kenzo Hirose; Takao Shimizu; Kazushige Touhara; Takashi Kadowaki
Journal:  Nature       Date:  2010-03-31       Impact factor: 49.962

4.  SIRT1 interacts with and protects glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from nuclear translocation: implications for cell survival after irradiation.

Authors:  Hyun-Yoo Joo; Seon Rang Woo; Yan-Nan Shen; Mi Yong Yun; Hyun-Jin Shin; Eun-Ran Park; Su-Hyeon Kim; Jeong-Eun Park; Yeun-Jin Ju; Sung Hee Hong; Sang-Gu Hwang; Myung-Haing Cho; Joon Kim; Kee-Ho Lee
Journal:  Biochem Biophys Res Commun       Date:  2012-07-10       Impact factor: 3.575

5.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

Authors:  Aimin Xu; Yu Wang; Hussila Keshaw; Lance Yi Xu; Karen S L Lam; Garth J S Cooper
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 6.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

7.  Mammalian sirtuin 1 is involved in the protective action of dietary saturated fat against alcoholic fatty liver in mice.

Authors:  Min You; Qi Cao; Xiaomei Liang; Joanne M Ajmo; Gene C Ness
Journal:  J Nutr       Date:  2008-03       Impact factor: 4.798

8.  Involvement of mammalian sirtuin 1 in the action of ethanol in the liver.

Authors:  Min You; Xiaomei Liang; Joanne M Ajmo; Gene C Ness
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-31       Impact factor: 4.052

9.  Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice.

Authors:  Hannah Everitt; Ming Hu; Joanne M Ajmo; Christopher Q Rogers; Xiaomei Liang; Ray Zhang; Huquan Yin; Alison Choi; Eric S Bennett; Min You
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-11-08       Impact factor: 4.052

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  15 in total

Review 1.  Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1.

Authors:  Min You; Alvin Jogasuria; Kwangwon Lee; Jiashin Wu; Yanqiao Zhang; Yoon Kwang Lee; Prabodh Sadana
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 2.  Sirtuin 1 signaling and alcoholic fatty liver disease.

Authors:  Min You; Alvin Jogasuria; Charles Taylor; Jiashin Wu
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

3.  Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice.

Authors:  Bruna Paola Murino Rafacho; Camilla Peach Stice; Chun Liu; Andrew S Greenberg; Lynne M Ausman; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

4.  Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice.

Authors:  Giridhar Kanuri; Marianne Landmann; Josephine Priebs; Astrid Spruss; Marina Löscher; Doreen Ziegenhardt; Carolin Röhl; Christian Degen; Ina Bergheim
Journal:  Eur J Nutr       Date:  2015-05-24       Impact factor: 5.614

5.  Sirtuin 1 attenuates inflammation and hepatocellular damage in liver transplant ischemia/Reperfusion: From mouse to human.

Authors:  Kojiro Nakamura; Shoichi Kageyama; Bibo Ke; Takehiro Fujii; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Liver Transpl       Date:  2017-10       Impact factor: 5.799

Review 6.  Insulin resistance in clinical and experimental alcoholic liver disease.

Authors:  Rotonya M Carr; Jason Correnti
Journal:  Ann N Y Acad Sci       Date:  2015-05-21       Impact factor: 5.691

Review 7.  Role of alcohol in the development and progression of hepatocellular carcinoma.

Authors:  Iain H McKillop; Laura W Schrum; Kyle J Thompson
Journal:  Hepat Oncol       Date:  2015-11-30

8.  Xanthophyll β-cryptoxanthin treatment inhibits hepatic steatosis without altering vitamin A status in β-carotene 9',10'-oxygenase knockout mice.

Authors:  Chun Liu; Bruna Paola M Rafacho; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 9.  Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD).

Authors:  Helmut K Seitz; Sebastian Mueller; Claus Hellerbrand; Suthat Liangpunsakul
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

10.  Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Shinya Furukawa; Osamu Yoshida; Mitsuhito Koizumi; Shin Yamamoto; Takao Watanabe; Yasunori Yamamoto; Yoshio Tokumoto; Eiji Takeshita; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2016-03-12       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.